If you need more lookups,
subscriptions start at $34 USD/month.
Venkat Ramakrishnan Location
Ellicott City, MD, US
Venkat Ramakrishnan Work
Regional Business Director - Oncology and Rare Diseases @ (August 2019 - Present)
Regional Oncology Business Director - Oncology and Rare Diseases @ (April 2017 - July 2019)
Sr. Regional Business Director - Southeast USA @ (December 2014 - March 2017)
Regional Business Manager @ Algeta ASA / Bayer (December 2012 - December 2014)
Regional Business Manager @ OSI Pharmaceuticals Inc / Astellas Pharmaceuticals (April 2009 - December 2012)
Regional Business Director @ ImClone Systems / Eli Lilly & Company (October 2003 - January 2009)
Venkat Ramakrishnan Education
Saint Joseph's University - Erivan K. Haub School of Business
MBA (MIS & MARKETING)
Venkat Ramakrishnan Skills
Biotechnology
Cancer
Cardiology
Clinical Research
Clinical Trials
Data-driven Decision Making
Endocrinology
Executive Visibility
Hematology
Infectious Diseases
Leadership
Managed Care
Market Research
Neurology
Oncology
Pharmaceutical Industry
Pharmaceutical Sales
Product Launch
Sales & Marketing Leadership
Sales Effectiveness
Sales Leadership
Sales Meetings
Strategy
Team Leadership
Urology
Research
Microsoft Excel
Sales and Marketing Leadership
Business Development
Strategic Planning
Public Speaking
Venkat Ramakrishnan Summary
Venkat Ramakrishnan, based in Ellicott City, MD, US, is currently a Regional Business Director - Oncology and Rare Diseases at Blueprint Medicines. Venkat Ramakrishnan brings experience from previous roles at Ipsen, Merrimack Pharmaceuticals, Algeta ASA / Bayer and OSI Pharmaceuticals Inc / Astellas Pharmaceuticals. Venkat Ramakrishnan holds a MBA in MIS & MARKETING @ Saint Joseph's University - Erivan K. Haub School of Business. With a robust skill set that includes Biotechnology, Cancer, Cardiology, Clinical Research, Clinical Trials and more. Venkat Ramakrishnan has 4 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Venkat Ramakrishnan?
Find contact details for 700 million professionals.